Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin A

Table 2

The main pharmacokinetic parameters of StA in the plasma of rats after intravenous or intragastric administration in four different ways (mean ± SD, ).

Parameters	Unit	Formulation 1	Formulation 2	Formulation 3
		Intragastric	Intravenous	Intravenous	Intragastric
	mg/L·h	18.38 ± 2.45	42.98 ± 4.59	67.67 ± 8.70	32.02 ± 12.51
	h	12.63 ± 1.24	8.58 ± 4.39	21.78 ± 2.24	11.46 ± 0.60
	h	12.61 ± 2.82	12.19 ± 5.24	15.88 ± 1.82	16.54 ± 6.95
CLz	L/h/kg	14.19 ± 2.28	578.76 ± 112.33	359.37 ± 56.65	828.40 ± 238.27
Vz	L/kg	253.29 ± 68.98	9625.04 ± 2762.20	8135.47 ± 488.59	21330 ± 14355.2
	h	4.167 ± 3.753	—	—	1.33 ± 0.58
	mg/L	1.11 ± 0.42	—	—	2.73 ± 1.32
/dose	kg/L·h	0.0613	1.432	2.256	1.0675
Bioavailability	—	4.30%	—	47.30%